Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Focus on Optimized Dosing of Ibrutinib Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Feb

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Focus on Optimized Dosing of Ibrutinib Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

HPV Testing During Cervical Cancer Screening Potential Convenient and Noninvasive Method

Guidelines Harmonize Pan-Tumor Pathologic Response to Neoadjuvant Therapy

Tissue-Free ctDNA and Outcomes in Patients With Colorectal Cancer Receiving FOLFOX-Based Adjuvant Therapy

Ultraprocessed Food Associated With Increased Mortality Risk in Cancer Survivors

A Paradigm Shift In Treating Adult AML?